# FDA Approves Sacituzumab Govitecan (Trodelvy) Plus Pembrolizumab (Keytruda) Combination for Triple-Negative Breast Cancer

> fda · REPORTED · 2026-06-24

The FDA approved the combination of sacituzumab govitecan (Trodelvy) and pembrolizumab (Keytruda) for triple-negative breast cancer in Q2 2026, based on the Phase III ASCENT-04/KEYNOTE-D19 trial which showed the combination reduced the risk of disease progression or death by 35% compared with Keytruda and chemotherapy. Results were presented at ASCO 2026 and published in the Journal of Clinical Oncology.

About Gilead / Trodelvy + Keytruda: Trodelvy (sacituzumab govitecan) is an antibody-drug conjugate developed by Gilead that targets Trop-2-expressing tumors and is approved for difficult-to-treat breast cancers including triple-negative breast cancer and HR-positive metastatic breast cancer.

- Company: Gilead / Trodelvy + Keytruda
- Sector: oncology
- Primary source: https://www.cancerhealth.com/article/fda-greenlights-five-new-treatment-options-breast-cancer

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.